阿片使用障碍患者直接向尿检样本添加丁丙诺啡与临床因素的相关性
直接添加与阿片阳性、初级保健场所、35-44岁年龄及南大西洋地区相关,年 prevalence 从2017年2.4%降至2020年1.2%。
要点
- 直接添加丁丙诺啡的样本占1.9%,涉及7.6%的患者。
- 阿片阳性样本(伴或不伴兴奋剂阳性)与直接添加正相关。
- 初级保健场所和35-44岁患者与直接添加正相关。
核心结论
- 直接向尿检样本添加丁丙诺啡与阿片阳性及初级保健场所采集相关,是临床重要发现。
主要发现
- 9546份(1.9%)样本来自4550名(7.6%)患者提示直接添加丁丙诺啡。
- 年 prevalence 从2017年2.4%下降至2020年1.2%。
- 阿片阳性伴兴奋剂阳性(aOR 2.01,95%CI 1.85-2.18)和不伴兴奋剂阳性(aOR 2.02,95%CI 1.81-2.26)与直接添加正相关。
- 35-44岁患者(aOR 1.59,95%CI 1.34-1.90)和初级保健场所(aOR 1.60,95%CI 1.44-1.79)与直接添加正相关。
- 南大西洋地区关联最高(aOR 1.4,95%CI 1.25-1.56),新英格兰最低(aOR 0.54,95%CI 0.46-0.65)。
关键数值与推荐
- 去甲丁丙诺啡与丁丙诺啡比值小于0.02定义为直接添加丁丙诺啡。
临床怎么用
- 临床应关注尿检中直接添加丁丙诺啡的现象,尤其在初级保健场所和阿片阳性患者中。
- 需制定针对该现象的最佳实践指南。
局限性
- 横断面设计无法推断因果关系。
- 未报告其他潜在混杂因素的控制情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The direct addition of buprenorphine to urine drug test specimens to mimic results suggestive of adherence is a clinically significant result, yet little is known about the phenomenon. OBJECTIVE: To characterize factors associated with the direct addition of buprenorphine to urine specimens among patients prescribed buprenorphine for opioid use disorder. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study of urine drug test specimens was conducted from January 1, 2017, to April 30, 2022, using a national database of urine drug test specimens ordered by clinicians from primary care, behavioral health, and substance use disorder treatment clinics. Urine specimens with quantitative norbuprenorphine and buprenorphine concentrations from patients with opioid use disorder currently prescribed buprenorphine were analyzed. EXPOSURES: Nonprescribed opioid or stimulant co-positive, clinical setting, collection year, census division, patient age, patient sex, and payor. MAIN OUTCOMES AND MEASURES: Norbuprenorphine to buprenorphine ratio less than 0.02 identified direct addition of buprenorphine. Unadjusted trends in co-positivity for stimulants and opioids were compared between specimens consistent with the direct addition of buprenorphine. Factors associated with the direct addition of buprenorphine were examined with generalized estimating equations. RESULTS: This study included 507 735 urine specimens from 58 476 patients. Of all specimens, 261 210 (51.4%) were obtained from male individuals, and 137 254 (37.7%) were from patients aged 25 to 34 years. Overall, 9546 (1.9%) specimens from 4550 (7.6%) patients were suggestive of the direct addition of buprenorphine. The annual prevalence decreased from 2.4% in 2017 to 1.2% in 2020. Opioid-positive with (adjusted odds ratio [aOR], 2.01; 95% CI, 1.85-2.18) and without (aOR, 2.02; 95% CI, 1.81-2.26) stimulant-positive specimens were associated with the direct addition of buprenorphine to specimens, while opioid-negative/stimulant-positive specimens were negatively associated (aOR, 0.78; 95% CI, 0.71-0.85). Specimens from patients aged 35 to 44 years (aOR, 1.59; 95% CI, 1.34-1.90) and primary care (aOR, 1.60; 95% CI, 1.44-1.79) were associated with the direct addition of buprenorphine. Differences by treatment setting decreased over time. Specimens from the South Atlantic census region had the highest association (aOR, 1.4; 95% CI, 1.25-1.56) and New England had the lowest association (aOR, 0.54; 95% CI, 0.46-0.65) with the direct addition of buprenorphine. CONCLUSIONS AND RELEVANCE: In this cross-sectional study, the direct addition of buprenorphine to urine specimens was associated with other opioid positivity and being collected in primary care settings. The direct addition of buprenorphine to urine specimens is a clinically significant finding, and best practices specific for this phenomenon are needed.
引用
- Pytell JD, Whitley P, Passik SD, et al. Association of Patients' Direct Addition of Buprenorphine to Urine Drug Test Specimens With Clinical Factors in Opioid Use Disorder. JAMA Psychiatry. 2023. PMID: 36947029. doi:10.1001/jamapsychiatry.2023.0234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。